Keywords: oscient, gains, expanded, global, rights, ramoplanin, massachusetts

Oscient gains expanded global rights to ramoplanin

Article | 13 February 2006

Massachusetts, USA-based Oscient Pharmaceuticals and Pfizer subsidiary Vicuron Pharmaceuticals have restructured the business relationship for the former's lead clinical candidate, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Pfizer

Go to company listing